Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Common Equity: 2019-2024

Historic Common Equity for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to -$1.5 billion.

  • BridgeBio Pharma's Common Equity fell 58.57% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 58.57%. This contributed to the annual value of -$1.5 billion for FY2024, which is 8.39% down from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Common Equity is -$1.5 billion, which was down 8.39% from -$1.4 billion recorded in FY2023.
  • In the past 5 years, BridgeBio Pharma's Common Equity ranged from a high of $106.3 million in FY2020 and a low of -$1.5 billion during FY2024.
  • Over the past 3 years, BridgeBio Pharma's median Common Equity value was -$1.4 billion (recorded in 2023), while the average stood at -$1.4 billion.
  • Data for BridgeBio Pharma's Common Equity shows a maximum YoY slumped of 915.96% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Common Equity stood at $106.3 million in 2020, then crashed by 915.96% to -$867.0 million in 2021, then tumbled by 43.41% to -$1.2 billion in 2022, then fell by 8.92% to -$1.4 billion in 2023, then dropped by 8.39% to -$1.5 billion in 2024.